Why Adaptive Biotechnologies Shares Are Rising
Adaptive Biotechnologies Corp (NASDAQ: ADPT) shares are trading higher by 12.58% to $7.25 after the company launched T-Detect Lyme, to help diagnose early lyme disease.
Piper Sandler Initiates Coverage On Adaptive Biotechnologies with Neutral Rating, Announces Price Target of $7.5
Piper Sandler analyst David Westenberg initiates coverage on Adaptive Biotechnologies (NASDAQ:ADPT) with a Neutral rating and announces Price Target of $7.5.
Goldman Sachs Maintains Neutral on Adaptive Biotechnologies, Lowers Price Target to $10
Goldman Sachs maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Neutral and lowers the price target from $14 to $10.
Adaptive Biotechnologies Earnings Perspective: Return On Capital Employed
Adaptive Biotechnologies (NASDAQ:ADPT) brought in sales totaling $38.62 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 2.35%, resulting in a loss of $62.80 million.
Earnings Scheduled For May 4, 2022
Companies Reporting Before The Bell
• Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 784 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday, 581 stocks hit new 52-week lows.
Interesting Highlights From Today's 52-Week Lows
Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.
